• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

立体定向体部放射治疗:一种用于不可切除肝细胞癌的新型治疗方式。

Stereotactic body radiation therapy: A novel treatment modality for inoperable hepatocellular carcinoma.

作者信息

Meng Maobin, Wang Huanhuan, Zeng Xianliang, Zhao Lujun, Yuan Zhiyong, Wang Ping, Hao Xishan

机构信息

Department of Radiation Oncology, CyberKnife Center, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute & Hospital.

出版信息

Drug Discov Ther. 2015 Oct;9(5):372-9. doi: 10.5582/ddt.2015.01056.

DOI:10.5582/ddt.2015.01056
PMID:26632546
Abstract

Hepatocellular carcinoma (HCC) is the most common malignancy in the world and the most common cause of cancer-related death. Surgical resection is the standard of care for solitary liver-confined HCC and provides the best long-term survival, however, most HCCs are diagnosed at an intermediate to advanced stage, and few meaningful therapeutic options are available at this point. Stereotactic body radiation therapy (SBRT) is a type of external beam radiation therapy (EBRT) that delivers radiotherapy (RT) accurately and precisely to the tumor, more so than conventionally fractionated RT. Several series report high rates of local control and low incidence of complications in SBRT for inoperable HCC. Herein, we discuss the emerging role of SBRT as well as current indications, implementation, efficacy and toxicities after SBRT. It was noted that SBRT was a safe and effective therapeutic option for HCC lesions unsuitable for standard locoregional therapies, with acceptable local control rates and low treatment-related toxicity. The significant correlation between local control (LC) and higher doses and between LC and overall survival (OS) supports the clinical value of SBRT in these patients.

摘要

肝细胞癌(HCC)是全球最常见的恶性肿瘤,也是癌症相关死亡的最常见原因。手术切除是孤立性肝内局限型HCC的标准治疗方法,可提供最佳的长期生存率。然而,大多数HCC在中晚期才被诊断出来,此时几乎没有有效的治疗选择。立体定向体部放射治疗(SBRT)是一种外照射放疗(EBRT),与传统分割放疗相比,它能更准确、精确地将放射治疗(RT)送达肿瘤部位。多个系列报道显示,SBRT治疗不可切除HCC的局部控制率高,并发症发生率低。在此,我们讨论SBRT的新兴作用以及SBRT后的当前适应证、实施方法、疗效和毒性。值得注意的是,SBRT对于不适合标准局部区域治疗的HCC病变是一种安全有效的治疗选择,具有可接受的局部控制率和较低的治疗相关毒性。局部控制(LC)与较高剂量之间以及LC与总生存期(OS)之间的显著相关性支持了SBRT在这些患者中的临床价值。

相似文献

1
Stereotactic body radiation therapy: A novel treatment modality for inoperable hepatocellular carcinoma.立体定向体部放射治疗:一种用于不可切除肝细胞癌的新型治疗方式。
Drug Discov Ther. 2015 Oct;9(5):372-9. doi: 10.5582/ddt.2015.01056.
2
The challenge of inoperable hepatocellular carcinoma (HCC): results of a single-institutional experience on stereotactic body radiation therapy (SBRT).不可切除肝细胞癌(HCC)的挑战:一项关于立体定向体部放射治疗(SBRT)的单机构经验结果
J Cancer Res Clin Oncol. 2015 Jul;141(7):1301-9. doi: 10.1007/s00432-015-1929-y. Epub 2015 Feb 3.
3
Stereotactic body radiation therapy in recurrent hepatocellular carcinoma.立体定向体部放疗在复发性肝细胞癌中的应用。
Int J Radiat Oncol Biol Phys. 2012 Oct 1;84(2):355-61. doi: 10.1016/j.ijrobp.2011.11.058. Epub 2012 Feb 17.
4
Stereotactic body radiotherapy for primary hepatocellular carcinoma.立体定向体部放疗治疗原发性肝癌。
Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e447-53. doi: 10.1016/j.ijrobp.2011.04.011. Epub 2011 Jun 7.
5
Preliminary result of stereotactic body radiotherapy as a local salvage treatment for inoperable hepatocellular carcinoma.立体定向体部放疗作为不可切除肝细胞癌局部挽救治疗的初步结果。
J Surg Oncol. 2010 Sep 1;102(3):209-14. doi: 10.1002/jso.21593.
6
Efficacy and Toxicity of Stereotactic Body Radiotherapy for Early to Advanced Stage Hepatocellular Carcinoma - Initial Experience From an Australian Liver Cancer Service.立体定向体部放疗治疗早期至晚期肝细胞癌的疗效和毒性 - 来自澳大利亚肝癌服务的初步经验。
Clin Oncol (R Coll Radiol). 2020 Oct;32(10):e194-e202. doi: 10.1016/j.clon.2020.04.004. Epub 2020 Apr 25.
7
Stereotactic body radiation therapy combined with transcatheter arterial chemoembolization for small hepatocellular carcinoma.立体定向体部放疗联合经导管动脉化疗栓塞治疗小肝癌。
J Gastroenterol Hepatol. 2013 Mar;28(3):530-6. doi: 10.1111/jgh.12087.
8
Stereotactic body radiation therapy for hepatocellular carcinoma.肝细胞癌的立体定向体部放射治疗
Discov Med. 2010 May;9(48):404-10.
9
Stereotactic body radiotherapy for small hepatocellular carcinoma: a retrospective outcome analysis in 185 patients.立体定向体部放疗治疗小肝癌:185 例回顾性结果分析。
Acta Oncol. 2014 Mar;53(3):399-404. doi: 10.3109/0284186X.2013.820342. Epub 2013 Aug 21.
10
Long term outcomes of stereotactic body radiation therapy for hepatocellular carcinoma without macrovascular invasion.无大血管侵犯肝细胞癌立体定向体部放疗的长期疗效。
Eur J Cancer. 2020 Jul;134:41-51. doi: 10.1016/j.ejca.2020.04.024. Epub 2020 May 24.

引用本文的文献

1
Radiofrequency ablation versus stereotactic body radiotherapy for recurrent hepatocellular carcinoma: a multicenter, propensity score matching analysis.射频消融术与立体定向体部放疗治疗复发性肝细胞癌的多中心倾向评分匹配分析
BMC Cancer. 2025 Mar 8;25(1):424. doi: 10.1186/s12885-025-13800-1.
2
A web-based nomogram model for predicting the overall survival of hepatocellular carcinoma patients with external beam radiation therapy: A population study based on SEER database and a Chinese cohort.基于 SEER 数据库和中国队列的人群研究:用于预测接受外照射放射治疗的肝细胞癌患者总生存期的基于网络的列线图模型。
Front Endocrinol (Lausanne). 2023 Jan 31;14:1070396. doi: 10.3389/fendo.2023.1070396. eCollection 2023.
3
Efficacy and acquired resistance for EGFR-TKI plus thoracic SBRT in patients with advanced EGFR-mutant non-small-cell lung cancer: a propensity-matched retrospective study.
在晚期 EGFR 突变型非小细胞肺癌患者中,EGFR-TKI 联合胸部 SBRT 的疗效和获得性耐药:一项倾向评分匹配的回顾性研究。
BMC Cancer. 2021 Apr 30;21(1):482. doi: 10.1186/s12885-021-08228-2.
4
HN1 as a diagnostic and prognostic biomarker for liver cancer.作为肝癌的诊断和预后生物标志物。
Biosci Rep. 2020 Jul 31;40(7). doi: 10.1042/BSR20200316.
5
Lobaplatin promotes I-induced apoptosis and inhibition of proliferation in hepatocellular carcinoma by upregulating PERK-eIF2α-ATF4-CHOP pathway.洛铂通过上调 PERK-eIF2α-ATF4-CHOP 通路促进 I 诱导的肝癌细胞凋亡和增殖抑制。
Cell Death Dis. 2019 Oct 3;10(10):744. doi: 10.1038/s41419-019-1918-1.
6
Comparing stereotactic ablative radiotherapy (SABR) versus re-trans-catheter arterial chemoembolization (re-TACE) for hepatocellular carcinoma patients who had incomplete response after initial TACE (TASABR): a randomized controlled trial.对比立体定向消融放疗(SABR)与再次经导管动脉化疗栓塞术(re-TACE)治疗初始 TACE 后不完全缓解的肝细胞癌患者(TASABR):一项随机对照试验。
BMC Cancer. 2019 Mar 28;19(1):275. doi: 10.1186/s12885-019-5461-3.
7
Goals and targets for personalized therapy for HCC.肝癌个体化治疗的目标和靶点。
Hepatol Int. 2019 Mar;13(2):125-137. doi: 10.1007/s12072-018-9919-1. Epub 2019 Jan 1.
8
Short-term outcomes and clinical efficacy of stereotactic body radiation therapy (SBRT) in treatment of adrenal gland metastases from lung cancer.立体定向体部放疗(SBRT)治疗肺癌肾上腺转移的短期疗效和临床疗效。
Radiat Oncol. 2018 Oct 22;13(1):205. doi: 10.1186/s13014-018-1152-5.
9
Hepatobiliary scintigraphy allows the evaluation of short-term functional toxicity of liver stereotactic body radiotherapy: Results of a pilot study.肝胆闪烁显像术可评估立体定向体部放疗的肝脏短期功能毒性:一项初步研究结果。
PLoS One. 2018 Oct 10;13(10):e0204013. doi: 10.1371/journal.pone.0204013. eCollection 2018.
10
Survival benefit of transarterial chemoembolization in patients with metastatic hepatocellular carcinoma: a single center experience.经动脉化疗栓塞术对转移性肝细胞癌患者的生存获益:单中心经验
BMC Gastroenterol. 2017 Aug 10;17(1):98. doi: 10.1186/s12876-017-0656-z.